Syros Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Syros Pharmaceuticals has a total shareholder equity of $16.7M and total debt of $41.2M, which brings its debt-to-equity ratio to 247.4%. Its total assets and total liabilities are $168.2M and $151.5M respectively.
Key information
247.4%
Debt to equity ratio
US$41.22m
Debt
Interest coverage ratio | n/a |
Cash | US$139.53m |
Equity | US$16.66m |
Total liabilities | US$151.51m |
Total assets | US$168.17m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0S90's short term assets ($145.0M) exceed its short term liabilities ($36.7M).
Long Term Liabilities: 0S90's short term assets ($145.0M) exceed its long term liabilities ($114.8M).
Debt to Equity History and Analysis
Debt Level: 0S90 has more cash than its total debt.
Reducing Debt: 0S90's debt to equity ratio has increased from 0% to 247.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0S90 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 0S90 has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of 20.7% each year.